Results 21 to 30 of about 81,803 (228)

BCR and its mutants, the reciprocal t(9;22)-associated ABL/BCR fusion proteins, differentially regulate the cytoskeleton and cell motility [PDF]

, 2006
Background The reciprocal (9;22) translocation fuses the bcr (breakpoint cluster region) gene on chromosome 22 to the abl (Abelson-leukemia-virus) gene on chromosome 9.
Martin Ruthardt, Beissert Tim, Ruthardt, Martin, Ruthardt Martin, Puccetti, Elena, Zheng Xiaomin, Elena Puccetti, Tim Beissert, Zheng, Xiaomin, Xiaomin Zheng, Beissert, Tim, Güller, Saskia, Güller Saskia, Saskia Güller, Puccetti Elena   +14 more
core   +2 more sources

Effect of HSP90AB1 and CC domain interaction on Bcr-Abl protein cytoplasm localization and function in chronic myeloid leukemia cells

Cell Communication and Signaling, 2021
Background The fusion oncoprotein Bcr-Abl is mostly located in the cytoplasm, which causes chronic myeloid leukemia (CML). After moving into the nucleus, the fusion protein can induce apoptosis of CML cells.
Yuhang Peng, Zhenglan Huang, Fangzhu Zhou, Teng Wang, Ke Mou, Wenli Feng   +5 more
doaj   +1 more source

Interactions of CBL with BCR-ABL and CRKL in BCR-ABL-transformed Myeloid Cells [PDF]

Journal of Biological Chemistry, 1997
The Philadelphia chromosome, detected in virtually all cases of chronic myelogenous leukemia (CML), is formed by a reciprocal translocation between chromosomes 9 and 22 that fuses BCR-encoded sequences upstream of exon 2 of c-ABL. The BCR-ABL fusion creates a gene whose protein product, p210BCR-ABL, has been implicated as the cause of the disease ...
A, Bhat, K, Kolibaba, T, Oda, S, Ohno-Jones, C, Heaney, B J, Druker   +5 more
openaire   +2 more sources

Targeting the oligomerization of BCR/ABL by membrane permeable competitive peptides inhibits the proliferation of Philadelphia Chromosome positive leukemic cells [PDF]

, 2013
The BCR/ABL fusion protein is the hallmark of Philadelphia Chromosome positive (Ph+) leukemia. The constitutive activation of the ABL-kinase in BCR/ABL cells induces the leukemic phenotype.
Mahajna, Jamal, Schüll, Marion, Najajreh, Yousef, Ruthardt, Martin, Oancea, Claudia, Goldblum, Amiram, Beißert, Tim, Ottmann, Oliver G., Mian, Afsar Ali   +8 more
core   +1 more source

I13 overrides resistance mediated by the T315I mutation in chronic myeloid leukemia by direct BCR-ABL inhibition

Frontiers in Pharmacology, 2023
Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm caused by a BCR-ABL fusion gene. Imatinib has significantly improved the treatment of CML as a first-generation tyrosine kinase inhibitor (TKIs). The T315I mutant form of BCR-ABL is the most
Congying Gao, Lei Zhang, Yun Xu, Xiangyu Ma, Peilei Chen, Zhe-Sheng Chen, Liuya Wei   +6 more
doaj   +1 more source

Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival [PDF]

, 2012
Recent evidence suggests CML stem cells are insensitive to kinase inhibitors and responsible for minimal residual disease in treated patients. We investigated whether CML stem cells, in a transgenic mouse model of CML-like disease or derived from ...
Allan, Elaine K., Mueller-Tidow, Carsten, Nicolini, Franck E., Bhatia, Ravi, Brunton, Valerie G, Myssina, Svetlana, Hamilton, Ashley, Mysina, Svetlana, Müller-Tidow, Carsten, Koschmieder, Steffen, Allan, Elaine K, Helgason, G. Vignir, Helgason, G Vignir, Brunton, Valerie G., Schemionek, Mirle, Zhang, Bin, Holyoake, Tessa L., Holyoake, Tessa L, Nicolini, Franck E   +18 more
core   +1 more source

Bcr/Abl Interferes with the Fanconi Anemia/BRCA Pathway: Implications in the Chromosomal Instability of Chronic Myeloid Leukemia Cells [PDF]

, 2010
Chronic myeloid leukemia (CML) is a malignant clonal disorder of the hematopoietic system caused by the expression of the BCR/ABL fusion oncogene. Although it is well known that CML cells are genetically unstable, the mechanisms accounting for this ...
Valeri, Antonio, Beatriz Albella, Agirre, Xabier, Casado, José A., Pujol, MR, Rio, P, Bueren, Juan, Ariana Jacome, Albella Beatriz, Maria Eugenia Alonso-Ferrero, Juan A Bueren, Alonso-Ferrero, Maria Eugenia, María Roser Pujol, Hanenberg, H. (H.), Jacome Ariana, Alonso-Ferrero, ME, Hanenberg, H, Perez, L, Pérez-Fuentes, L. (Laura), Agirre, X, Jacome, A, Juan A. Bueren, Jacome, Ariana, Río Paula, Pujol María Roser, Surrallés Jordi, Prosper-Cardoso, F. (Felipe), Pérez Laura, Maria José Calasanz, Surralles, J. (Jordi), Hanenberg, Helmut, Prosper Felipe, Helmut Hanenberg, Pérez, Laura, Casado, J. (J.A.), Jacome, A. (Ariana), Albella, Beatriz, Bueren, JA, Hanenberg Helmut, Agirre Xabier, Bueren, J.A. (Juan A.), Valeri, A. (Antonio), Rio, P. (Paula), Calasanz-Abinzano, M.J. (Maria Jose), Prosper, F, José A Casado, Laura Pérez, Paula Río, Río, Paula, Antonio Valeri, Casado José A., Valeri Antonio, Jordi Surrallés, Casado, JA, Calasanz Maria José, Felipe Prosper, Surralles, J, José A. Casado, Calasanz, MJ, Albella, B, Albella, B. (B.), Alonso-Ferrero Maria Eugenia, Valeri, A, Alonso-Ferrero, M. (M.E.), Pujol, M.R. (María Roser), Bueren Juan A., Aguirre-Ena, X. (Xabier), Xabier Agirre, Prosper, Felipe, Calasanz, M.J., Pujol Calvet, Maria Roser, Surralles, Jordi   +71 more
core   +2 more sources

Pterostilbene downregulates BCR/ABL and induces apoptosis of T315I-mutated BCR/ABL-positive leukemic cells

Scientific Reports, 2022
In this study, we examined the antileukemic effects of pterostilbene, a natural methylated polyphenol analog of resveratrol that is predominantly found in berries and nuts, using various human and murine leukemic cells, as well as bone marrow samples ...
Shohei Kawakami, Mitsuyo Tsuma-Kaneko, Masakazu Sawanobori, Tomoko Uno, Yoshihiko Nakamura, Hideyuki Matsuzawa, Rikio Suzuki, Makoto Onizuka, Takashi Yahata, Kazuhito Naka, Kiyoshi Ando, Hiroshi Kawada   +11 more
doaj   +1 more source

Association of Clinical Features and Hematological Laboratories between Ph (+)/BCR-ABL (+) Chronic Myeloid Leukemia and Other Type of Ph/BCR-ABL Chronic Myeloid Leukemia

Jurnal Penyakit Dalam Indonesia, 2018
Introduction. Patients with chronic phase Chronic Myeloid Leukemia (CML) at Hematology-Medical Oncology Clinic Department of Internal Medicine dr. Cipto Mangunkusumo National Hospital who haveperformed cytogenetic and RTPCR BCR-ABL examination showed: Ph
Wulyo Rajabto, A. Harryanto, Hilman Tadjoedin, Kuntjoro Harimurti   +3 more
doaj   +1 more source

Suppression of autophagy by BCR ABL

Frontiers in Bioscience, 2012
Imatinib and second generation BCR/ABL tyrosine kinase inhibitors (TKIs) serve now as standard therapies for patients with chronic myelogenous leukemia (CML); however, CML stem cells are intrinsically insensitive to the cell death-inducing effects of TKIs, allowing the persistence of a "reservoir" of BCR/ABL-expressing CML-initiating cells potentially ...
CALABRETTA, Bruno, SALOMONI, Paolo
openaire   +4 more sources